Alicaforsen - Atlantic Healthcare
Alternative Names: Alicaforsen enema; Alicaforsen sodium; AP 1007; AP 1431; AP 1450; AP 1451; Camligo; ISIS 2302Latest Information Update: 05 Sep 2022
At a glance
- Originator Isis Pharmaceuticals
- Developer Atlantic Healthcare
- Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
- Mechanism of Action Immunosuppressants; Intercellular adhesion molecule-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis
Highest Development Phases
- Phase III Crohn's disease
- Phase II Ulcerative colitis
- No development reported Pouchitis
- Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis
Most Recent Events
- 15 Aug 2022 Ionis Pharmaceuticals completes phase III clinical trials in Crohn's disease in Belgium, Czech Republic, Germany, Italy, Poland, Spain (IV) (NCT00048295)
- 02 Feb 2022 Atlantic Healthcare has patent protection for Alicaforsen in USA for the treatment of inflammatory bowel disease
- 03 Oct 2021 Updated adverse events, efficacy and pharmacokinetics data from a phase III trial in Pouchitis presents at the 29th United European Gastroenterology Week (UEGW-2021)